Comparison between Nephro Care IPO and Visaman Global Sales IPO.
Nephro Care IPO is a SME Fixed Price IPO proposed to list at NSE SME while Visaman Global Sales IPO is a SME Fixed Price proposed to list at NSE SME.
| Nephro Care IPO | Visaman Global Sales IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Corporate Capitalventures Pvt.Ltd. | Shreni Shares Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | SS Corporate Securities Ltd. | Shreni Shares Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Nephro Care IPO is up to ₹39.18 Cr whereas the issue size of the Visaman Global Sales IPO is up to ₹15.22 Cr. The final issue price of Nephro Care IPO is ₹90.00 per share and of Visaman Global Sales IPO is ₹43.00 per share.
| Nephro Care IPO | Visaman Global Sales IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹85.00 per share | |
| Issue Price (Upper) | ₹90.00 per share | |
| Issue Price (Final) | ₹90.00 per share | ₹43.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 1600 shares | 3000 shares |
| Fresh Issue Size | 43,53,600 shares | 35,40,000 shares |
| Fresh Issue Size (Amount) | up to ₹39.18 Cr | up to ₹15.22 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 43,53,600 shares | 35,40,000 shares |
| Issue Size Total (Amount) | up to ₹39.18 Cr | up to ₹15.22 Cr |
Nephro Care IPO opens on Jun 28, 2024, while Visaman Global Sales IPO opens on Jun 24, 2024. The closing date of Nephro Care IPO and Visaman Global Sales IPO is Jul 02, 2024, and Jun 26, 2024, respectively.
| Nephro Care IPO | Visaman Global Sales IPO | |
|---|---|---|
| Anchor Bid Date | Jun 27, 2024 | |
| Issue Open | Jun 28, 2024 | Jun 24, 2024 |
| Issue Close | Jul 02, 2024 | Jun 26, 2024 |
| Basis Of Allotment (Tentative) | Jul 03, 2024 | Jun 27, 2024 |
| Initiation of Refunds (Tentative) | Jul 04, 2024 | Jun 28, 2024 |
| Credit of Share (Tentative) | Jul 04, 2024 | Jun 28, 2024 |
| Listing date (Tentative) | Jul 05, 2024 | Jul 01, 2024 |
| Anchor Lockin End date 1 | Aug 02, 2024 | |
| Anchor Lockin End date 2 | Oct 01, 2024 |
Nephro Care IPO P/E ratio is 55.15, as compared to Visaman Global Sales IPO P/E ratio of 38.25.
| Nephro Care IPO | Visaman Global Sales IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Nephro Care India Limited Financial Information (Restated)Nephro Care India Limited's revenue increased by 398.84% and profit after tax (PAT) rose by 19920.41% between the financial year ending with March 31, 2023 and March 31, 2022.
| Visaman Global Sales Limited Financial Information (Restated)Visaman Global Sales Limited's revenue increased by 16.04% and profit after tax (PAT) rose by 19.72% between the financial year ending with March 31, 2023 and March 31, 2022.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 85.02 | 100.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 61.39 | 72.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 55.15 | 38.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹148.38 Cr. | ₹59.39 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 41.57% | 9.28% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 36.56% | 8.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 5.20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹1.63 | ₹1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 24.42% | 9.28% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Nephro Care IPO Retail Individual Investors (RII) are offered 14,44,800 shares while in Visaman Global Sales IPO retail investors are offered 14,44,800 shares. Qualified Institutional Buyers (QIB) are offered 8,25,600 shares in Nephro Care IPO and in Visaman Global Sales IPO.
| Nephro Care IPO | Visaman Global Sales IPO | |
|---|---|---|
| Anchor Investor Reserveration | 12,38,400 shares | |
| Market Maker Reserveration | 2,30,400 shares | 1,92,000 shares |
| QIB | 8,25,600 shares | |
| NII | 6,19,200 shares | 17,70,000 shares |
| RII | 14,44,800 shares | 17,70,000 shares |
| Employee | 2,25,600 shares | |
| Others | ||
| Total | 43,53,600 shares | 35,40,000 shares |
Nephro Care IPO subscribed 715.78x in total, whereas Visaman Global Sales IPO subscribed 42.20x.
| Nephro Care IPO | Visaman Global Sales IPO | |
|---|---|---|
| QIB (times) | 245.14x | |
| NII (times) | 1,787.19x | 28.12x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 634.12x | 51.54x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 715.78x | 42.20x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
